# US 2026/0209330 A1 · S100a7 as a diagnostic marker and therapeutic target for disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209330 A1
- Document ID: US20260209330A1
- Status: Published application
- Kind: A1
- Application number: 19/134,433
- Filed: 2023-12-01
- Published: 2026-07-23
- Earliest claimed: 2022-12-02
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Ramesh GANJU; Sanjay MISHRA; Manish CHARAN
- Web page: https://patentgrep.com/patent/US20260209330A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/30: from tumour cells
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/49: Breast
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosures relates to S100A7 inhibitors and uses thereof for treatment of obesity or obesity-associated diseases. The present disclosures also relates to S100A7 as a biomarker for diagnosing, monitoring, and/or treating obesity or obesity-associated diseases.

## Claims

### Claim 1

A recombinant antibody that specifically binds to a S100A7 polypeptide.

### Claim 2 (depends on 1)

The recombinant antibody of claim 1, wherein the recombinant antibody comprises at least one heavy chain and/or at least one light chain.

### Claim 3 (depends on 2)

The recombinant antibody of claim 2, wherein the heavy chain comprises at least one heavy chain complementarity determining region (CDRH) selected from CDRH1, CDRH2, and CDRH3.

### Claim 4 (depends on 3)

The recombinant antibody of claim 3, wherein the CDRH1 comprises a sequence at least about 80% identical to SEQ ID NO: 1 or a fragment thereof.

### Claim 5 (depends on 3)

The recombinant antibody of claim 3, wherein the CDRH2 comprises a sequence at least about 80% identical to SEQ ID NO: 2 or a fragment thereof.

### Claim 6 (depends on 3)

The recombinant antibody of claim 3, wherein the CDRH3 comprises a sequence at least about 80% identical to SEQ ID NO: 3 or a fragment thereof.

### Claim 7 (depends on 2)

The recombinant antibody of claim 2, wherein the heavy chain comprises a sequence at least about 80% identical to SEQ ID NO: 4 or a fragment thereof.

### Claim 8 (depends on 2)

The recombinant antibody of claim 2, wherein the light chain comprises at least one light chain complementarity determining region (CDRL) selected from CDRL1, CDRL2, and CDRL3.

### Claim 9 (depends on 8)

The recombinant antibody of claim 8, wherein the CDRL1 comprises a sequence at least about 80% identical to SEQ ID NO: 5 or a fragment thereof.

### Claim 10 (depends on 8)

The recombinant antibody of claim 8, wherein the CDRL2 comprises a sequence at least about 80% identical to SEQ ID NO: 6 or a fragment thereof.

### Claim 11 (depends on 8)

The recombinant antibody of claim 8, wherein the CDRL3 comprises a sequence at least about 80% identical to SEQ ID NO: 7 or a fragment thereof.

### Claim 12 (depends on 2)

The recombinant antibody of claim 2, wherein the light chain comprises a sequence at least about 80% identical to SEQ ID NO: 8 or a fragment thereof.

### Claim 13 (depends on 1)

A recombinant polynucleotide encoding the recombinant antibody of claim 1.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the recombinant antibody of claim 1.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, further comprising a cytosolic phospholipase A2 (cPLA2) inhibitor, a solute carrier family 6 member 2 (SLC6A2) inhibitor, a PD-L1 inhibitor, PD-1 inhibitor, or a combination thereof.

### Claim at position 16

-23. (canceled)

### Claim 24

A method of treating obesity or an obesity-associated disorder in a subject in need thereof comprising:
determining if the subject has obesity or an obesity-associated disorder; and
administering to the subject a therapeutically effective amount of an S100A7 inhibitor if the subject is determined to have obesity or an obesity-associated disorder.

### Claim 25 (depends on 24)

The method of claim 24, wherein the subject is determined to have obesity or an obesity-associated disorder if the subject has an increased level of an S100A7 polypeptide in a biological sample obtained from the subject in comparison to a reference control.

### Claim 26 (depends on 24)

The method of claim 24, wherein the S100A7 inhibitor is a polypeptide, a polynucleotide, a small molecule, or a gene editing system.

### Claim 27 (depends on 26)

The method of claim 26, wherein the polynucleotide is a siRNA or a shRNA that targets an S100A7 polynucleotide.

### Claim 28 (depends on 26)

The method of claim 26, wherein the gene editing system is a CRISPR/Cas endonuclease system comprising a guide RNA (gRNA) targeting an S100A7 polynucleotide.

### Claim at position 22

-82. (canceled)
